Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rasburicase for severe tophaceous gout
2020-002758-25Phase 2Completed
- Sponsor
- Reade
- Start
- Mar 2023
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rasburicase in gout, sponsored by Reade. Primary endpoint: Serum uric acid level. Started Mar 2023; status: completed.
02
Drugs
rasburicase
03
Conditions
gout
Beyond the preview
Go deeper on 2020-002758-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002758-25.